| 摘要 |
<p>Hybride cell lineages capable of secreting anti-idiotypic antibodies directed against an anti-ligand immunoglobuline; said cell lineages obtained by fusion are successively selected according to the following cumulative criteria: a) the antibodies they secrete are capable of recognizing the idiotypic monoclonal anti-body; b) the antibodies they secrete are capable of inhibiting the fixation of the ligand and/or of the agonists and/or the antagonists of said ligand; c) the antibodies they secrete are capable of recognizing cells or cells constituents carrying the receiver of said ligand. The invention also relates to a process for the preparation of said cell lineages, the new monoclonal antibodies secreted by these hybride cells, and their utilization particularly as marker reactance of the ligand receiver or as active ingredients in the preparation of agonist and antagonist drugs of said ligand.</p> |
